Vaccinex Financial Statements From 2010 to 2024

VCNX Stock  USD 7.45  0.10  1.32%   
Vaccinex financial statements provide useful quarterly and yearly information to potential Vaccinex investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vaccinex financial statements helps investors assess Vaccinex's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vaccinex's valuation are summarized below:
Gross Profit
-13.7 M
Market Capitalization
8.8 M
Enterprise Value Revenue
14.4969
Revenue
795 K
Earnings Share
(83.86)
We have found one hundred twenty available fundamental trend indicators for Vaccinex, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vaccinex current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Vaccinex financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaccinex main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 19.7 K or Depreciation And Amortization of 282.2 K, as well as many exotic indicators such as Price To Sales Ratio of 2.2 K, Dividend Yield of 0.0 or Operating Cycle of 444. Vaccinex financial statements analysis is a perfect complement when working with Vaccinex Valuation or Volatility modules.
  
This module can also supplement Vaccinex's financial leverage analysis and stock options assessment as well as various Vaccinex Technical models . Check out the analysis of Vaccinex Correlation against competitors.
For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.

Vaccinex Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.1 M9.2 M6.7 M
Slightly volatile
Short and Long Term Debt Total414.7 K436.5 K2.6 M
Pretty Stable
Other Current Liabilities667.8 K702.9 K1.9 M
Slightly volatile
Total Current Liabilities2.2 M2.3 M4.7 M
Very volatile
Other Liabilities425.2 K332.1 K522 K
Slightly volatile
Property Plant And Equipment Net443.7 K449.1 K610.3 K
Slightly volatile
Accounts Payable1.8 M1.4 M2.2 M
Slightly volatile
Cash6.3 M7.3 M4.2 M
Slightly volatile
Non Current Assets Total443.7 K449.1 K610.3 K
Slightly volatile
Long Term Debt86.4 K90.9 K928.5 K
Slightly volatile
Cash And Short Term Investments8.5 M7.3 M5.3 M
Slightly volatile
Common Stock Shares Outstanding3.4 M3.3 M962.6 K
Slightly volatile
Long Term Debt Total2.1 M3.2 MM
Slightly volatile
Liabilities And Stockholders Equity10.1 M9.2 M6.7 M
Slightly volatile
Capital Surpluse148.1 M255.8 M128.8 M
Slightly volatile
Other Current Assets735.7 KM569.9 K
Slightly volatile
Other Stockholder Equity226.3 M373.6 M159.8 M
Slightly volatile
Total Liabilities2.4 M2.5 M5.9 M
Slightly volatile
Property Plant And Equipment Gross9.4 M8.9 M2.7 M
Slightly volatile
Short and Long Term Debt63.3 K66.6 K2.3 M
Pretty Stable
Preferred Stock Total Equity127 M137.3 M117.4 M
Slightly volatile
Total Current Assets9.5 M8.6 M6.1 M
Slightly volatile
Non Current Liabilities Other118.5 M128.5 M109.6 M
Slightly volatile
Short Term Debt203.5 K214.2 K2.3 M
Pretty Stable
Common StockK5.8 K2.2 K
Slightly volatile
Property Plant Equipment451.1 K394.2 K603.1 K
Slightly volatile
Current Deferred Revenue238.4 K268.2 K292 K
Slightly volatile
Common Stock Total Equity1.8 K3.5 K1.6 K
Slightly volatile
Capital StockK5.8 K2.2 K
Slightly volatile
Inventory0.80.90.98
Slightly volatile

Vaccinex Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income19.7 K20.7 K3.1 M
Slightly volatile
Depreciation And Amortization282.2 K345 K232.7 K
Slightly volatile
Selling General Administrative6.4 M6.9 M5.3 M
Slightly volatile
Total Revenue456.9 K620 K378.4 K
Pretty Stable
Other Operating Expenses27.4 M23 M23.2 M
Slightly volatile
Research Development15 M17 M17.4 M
Pretty Stable
Cost Of Revenue215.4 K186.3 K198.4 K
Pretty Stable
Total Operating Expenses27 M23.6 M23.1 M
Slightly volatile
Reconciled Depreciation171.2 K137 K207.4 K
Pretty Stable

Vaccinex Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock44.8 M42.7 M23.7 M
Slightly volatile
Stock Based Compensation467.2 K502 K311.7 K
Slightly volatile
Begin Period Cash Flow6.4 M7.2 M5.8 M
Pretty Stable
Depreciation167.6 K137 K194.1 K
Pretty Stable
Capital Expenditures61.8 K65 K432 K
Slightly volatile
Total Cash From Financing Activities18.3 M11.2 M20 M
Pretty Stable
End Period Cash Flow120.7 K127 K3.3 M
Slightly volatile
Issuance Of Capital Stock18.7 M11.3 M30.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.2 K3.4 K1.9 K
Slightly volatile
Operating Cycle444575380
Slightly volatile
Price Earnings To Growth Ratio0.320.410.4138
Pretty Stable
Days Of Payables Outstanding2.3 K2.4 K43.6 K
Pretty Stable
Ebt Per Ebit0.760.90.8302
Slightly volatile
Payables Turnover0.140.160.101
Slightly volatile
Cash Per Share2.482.6120.3389
Slightly volatile
Quick Ratio1.42.331.2224
Slightly volatile
Dividend Paid And Capex Coverage Ratio220173164
Slightly volatile
Net Income Per E B T0.810.90.9835
Slightly volatile
Cash Ratio2.382.271.1098
Slightly volatile
Days Of Inventory Outstanding0.00190.0020.0139
Pretty Stable
Days Of Sales Outstanding444575380
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.161.0389
Pretty Stable
Current Ratio1.542.651.3649
Slightly volatile
Fixed Asset Turnover0.170.180.5323
Very volatile
Capital Expenditure Coverage Ratio220173164
Slightly volatile
Debt Ratio0.06640.06990.3771
Pretty Stable
Price Sales Ratio2.2 K3.4 K1.9 K
Slightly volatile
Receivables Turnover1.180.661.8037
Slightly volatile
Asset Turnover0.01370.01440.0718
Slightly volatile

Vaccinex Fundamental Market Drivers

Cash And Short Term Investments6.4 M

Vaccinex Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Vaccinex Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Vaccinex income statement, its balance sheet, and the statement of cash flows. Vaccinex investors use historical funamental indicators, such as Vaccinex's revenue or net income, to determine how well the company is positioned to perform in the future. Although Vaccinex investors may use each financial statement separately, they are all related. The changes in Vaccinex's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vaccinex's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vaccinex Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vaccinex. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue268.2 K238.4 K
Total Revenue620 K456.9 K
Cost Of Revenue186.3 K215.4 K
Ebit Per Revenue(228.92)(240.36)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vaccinex in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vaccinex's short interest history, or implied volatility extrapolated from Vaccinex options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vaccinex offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vaccinex's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vaccinex Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vaccinex Stock:
Check out the analysis of Vaccinex Correlation against competitors.
For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Vaccinex Stock analysis

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is Vaccinex's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaccinex. If investors know Vaccinex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaccinex listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(83.86)
Revenue Per Share
2.987
Quarterly Revenue Growth
(0.60)
Return On Assets
(2.58)
Return On Equity
(17.98)
The market value of Vaccinex is measured differently than its book value, which is the value of Vaccinex that is recorded on the company's balance sheet. Investors also form their own opinion of Vaccinex's value that differs from its market value or its book value, called intrinsic value, which is Vaccinex's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaccinex's market value can be influenced by many factors that don't directly affect Vaccinex's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaccinex's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaccinex is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaccinex's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.